07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

Emulsified Influenza HA Vaccine regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved Emulsified Influenza HA Vaccine, an H5N1 adjuvanted prophylactic pandemic influenza vaccine, from Kaketsuken and partner GlaxoSmithKline. The intramuscular vaccine uses the EB66 cell line from...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

Cell culture-based pandemic influenza vaccine regulatory update

Daiichi Sankyo said its Kitasato Daiichi Sankyo Vaccine Co. Ltd. subsidiary submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a cell culture-based pandemic influenza vaccine. Kitasato Daiichi received a grant...
00:56 , Jun 20, 2013 |  BC Extra  |  Company News

Daiichi seeking Japanese approval of pandemic flu vaccine

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said its Kitasato Daiichi Sankyo Vaccine Co. Ltd. subsidiary submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a cell culture-based pandemic influenza vaccine. Kitasato...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Cell culture-based pandemic influenza vaccine regulatory update

Vivalis S.A. (Euronext:VLS, Nantes, France) said Kaketsuken (formerly the Chemo-Sero-Therapeutic Research Institute) submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a cell culture-based, H5N1 adjuvanted pandemic influenza vaccine. In 2009,...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

Cell culture-based pandemic influenza vaccine: Phase III started

Vivalis S.A. (Euronext:VLS, Nantes, France) said GlaxoSmithKline and Kaketsuken began a Japanese Phase III trial to evaluate a cell culture-based pandemic flu vaccine in healthy adults. In 2009, GlaxoSmithKline and Kaketsuken (formerly the Chemo-Sero-Therapeutic Research...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

Cell culture based pandemic influenza vaccine: Phase II started

Vivalis S.A. (Euronext:VLS, Nantes, France) said Kaketsuken began in April a Japanese Phase II trial to evaluate a cell culture-based pandemic flu vaccine. In 2009, GlaxoSmithKline and Kaketsuken (formerly the Chemo-Sero-Therapeutic Research Institute) partnered to...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Iomai, GlaxoSmithKline, Novartis, U.S. Department of Health and Human Services infectious news

HHS awarded $132.5 million to three companies to develop adjuvant-based vaccines and adjuvants for H5N1 avian influenza. GSK will receive $63.3 million over five years for vaccine R&D, and the U.S. government also may opt...
01:14 , Jan 18, 2007 |  BC Extra  |  Top Story

HHS awards $132.5M for avian flu vaccines

The U.S. Department of Health and Human Services awarded a total of $132.5 million to three companies to develop adjuvant-based vaccines and adjuvants for H5N1 avian influenza. GlaxoSmithKline (LSE:GSK; GSK) will receive $63.3 million over...